Loading clinical trials...

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients | Clinical Trials | Clareo Health

COMPLETEDPhase 1NCT02099591

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.

Lead sponsor: Kyowa Kirin Pharmaceutical Development Ltd•16 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment61

Start dateNov 2014

Last updatedJun 17, 2024

Condition

Constipation, Signs and Symptoms, Digestive

Locations shown

Odense University Hospital

Odense

Rambam Medical Center, Oncology Institute

Haifa

Schneider Children Medical Center

Petah Tikva

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 17, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions